Company profile: Remedy Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage small molecule drug therapies for acute central nervous system disorders, developing treatments that target NCCa-ATP channels in traumatic brain injury, stroke, and spinal cord injury, including RP-1127, an intravenous glyburide inhibitor acting through type-1 sulfonylurea antagonism.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Remedy Pharmaceuticals
Chase Therapeutics
HQ: United States
Website
- Description: Provider of early-stage, product-based specialty pharmaceuticals, including CTC-413 for symptomatic and neuroprotective treatment of Parkinson’s disease and related disorders (Phase 2), CTC-501 for symptomatic treatment of major depressive disorder (Phase 2), and a Parkinson’s disease bioassay for diagnosis and immediate-response outcome measurement in clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chase Therapeutics company profile →
Diagnamed
HQ: Canada
Website
- Description: Provider of digital health AI platforms and tools to improve brain health, including BRAIN AGE AI for estimating brain age and assessing cognitive decline using EEG and machine learning; CERVAI Brain Health AI for assessments and research with generative AI; Dr. GenAI, a healthcare chatbot; PalGPT.ai for brain health applications; and FormGPT.io for healthcare applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnamed company profile →
Cypress Bioscience
HQ: United States
Website
- Description: Provider of therapeutics and personalized medicine services to facilitate individualized patient care, addressing needs such as isolated areas of pain, rheumatology, and physical medicine and rehabilitation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cypress Bioscience company profile →
Quadrant Biosciences
HQ: United States
Website
- Description: Provider of epigenetic diagnostics focused on early detection of neurological disorders, offering: a virtual pediatric clinic for autism evaluations via telehealth; molecular diagnostics for COVID-19, autism and Parkinson’s; autism assessment workflow software; and wastewater monitoring for SARS-CoV-2 and other pathogens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quadrant Biosciences company profile →
Cantabio Pharmaceuticals
HQ: United States
Website
- Description: Provider of preclinical biotechnology drug discovery research and therapeutic development focused on neurodegenerative and metabolic diseases, developing small-molecule DJ-1 protein-targeting therapeutics for Parkinson’s and other conditions and Tau protein-targeting therapeutics for Alzheimer’s and related tauopathies, integrating biophysics and novel technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cantabio Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Remedy Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Remedy Pharmaceuticals
2.2 - Growth funds investing in similar companies to Remedy Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Remedy Pharmaceuticals
4.2 - Public trading comparable groups for Remedy Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →